Annovis Bio, Inc.

NYSE ANVS

Annovis Bio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -30.40 M

Annovis Bio, Inc. EBITDA is USD -30.40 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Annovis Bio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Annovis Bio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00, a 0.00% change year over year.
Annovis Bio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 0.00, a -100.00% change year over year.
Annovis Bio, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 1.32 M, a 408.36% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NYSE: ANVS

Annovis Bio, Inc.

CEO	Mr. Mark K. White
IPO Date	Jan. 29, 2020
Location	United States
Headquarters	1055 Westlakes Drive
Employees	6
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Key trends

Past 5 years